ID   ABCC8_HUMAN             Reviewed;        1581 AA.
AC   Q09428; A6NMX8; E3UYX6; O75948; Q16583;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 6.
DT   10-MAY-2017, entry version 183.
DE   RecName: Full=ATP-binding cassette sub-family C member 8;
DE   AltName: Full=Sulfonylurea receptor 1;
GN   Name=ABCC8; Synonyms=HRINS, SUR, SUR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Heart;
RX   PubMed=21671119; DOI=10.1007/s00018-011-0739-x;
RA   Schmid D., Stolzlechner M., Sorgner A., Bentele C., Assinger A.,
RA   Chiba P., Moeslinger T.;
RT   "An abundant, truncated human sulfonylurea receptor 1 splice variant
RT   has prodiabetic properties and impairs sulfonylurea action.";
RL   Cell. Mol. Life Sci. 69:129-148(2012).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], ALTERNATIVE SPLICING, AND
RP   VARIANT SER-1369.
RC   TISSUE=Pancreatic islet;
RA   Gonzalez G., Aguilar-Bryan L., Bryan J.;
RT   "Human beta cell sulfonylurea receptor, SUR1, expression.";
RL   Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), VARIANT
RP   SER-1369, AND VARIANT PNDM PRO-225.
RC   TISSUE=Brain, and Foreskin;
RA   Thomas P.T., Wohllk N., Huang E., Gagel R.F., Cote G.J.;
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT SER-1369.
RC   TISSUE=Pancreas;
RA   Nishimura M., Miki T., Aizawa T., Seino S.;
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1187-1581, AND VARIANT SER-1369.
RC   TISSUE=Pancreatic islet;
RX   PubMed=7716548; DOI=10.1126/science.7716548;
RA   Thomas P.M., Cote G.J., Wohllk N., Haddad B., Mathew P.M., Rabl W.,
RA   Aguilar-Bryan L., Gagel R.F., Bryan J.;
RT   "Mutations in the sulfonylurea receptor gene in familial persistent
RT   hyperinsulinemic hypoglycemia of infancy.";
RL   Science 268:426-429(1995).
RN   [7]
RP   TOPOLOGY.
RX   PubMed=10506167; DOI=10.1074/jbc.274.41.29122;
RA   Raab-Graham K.F., Cirilo L.J., Boettcher A.A., Radeke C.M.,
RA   Vandenberg C.A.;
RT   "Membrane topology of the amino-terminal region of the sulfonylurea
RT   receptor.";
RL   J. Biol. Chem. 274:29122-29129(1999).
RN   [8]
RP   REVIEW.
RX   PubMed=10204114; DOI=10.1210/edrv.20.2.0361;
RA   Aguilar-Bryan L., Bryan J.;
RT   "Molecular biology of adenosine triphosphate-sensitive potassium
RT   channels.";
RL   Endocr. Rev. 20:101-135(1999).
RN   [9]
RP   REVIEW ON VARIANTS.
RX   PubMed=10338089;
RX   DOI=10.1002/(SICI)1098-1004(1999)13:5<351::AID-HUMU3>3.0.CO;2-R;
RA   Meissner T., Beinbrech B., Mayatepek E.;
RT   "Congenital hyperinsulinism: molecular basis of a heterogeneous
RT   disease.";
RL   Hum. Mutat. 13:351-361(1999).
RN   [10]
RP   VARIANT HHF1 VAL-716.
RX   PubMed=8751851;
RA   Thomas P.M., Wohllk N., Huang E., Kuhnle U., Rabl W., Gagel R.F.,
RA   Cote G.J.;
RT   "Inactivation of the first nucleotide-binding fold of the sulfonylurea
RT   receptor, and familial persistent hyperinsulinemic hypoglycemia of
RT   infancy.";
RL   Am. J. Hum. Genet. 59:510-518(1996).
RN   [11]
RP   VARIANT SER-1369.
RX   PubMed=8635661; DOI=10.2337/diab.45.6.825;
RA   Inoue H., Ferrer J., Welling C.M., Elbein S.C., Hoffman M.,
RA   Mayorga R., Warren-Perry M., Zhang Y., Millns H., Turner R.,
RA   Province M., Bryan J., Permutt M.A., Aguilar-Bryan L.;
RT   "Sequence variants in the sulfonylurea receptor (SUR) gene are
RT   associated with NIDDM in Caucasians.";
RL   Diabetes 45:825-831(1996).
RN   [12]
RP   VARIANT HHF1 PHE-1387 DEL, AND VARIANTS GLY-1360; SER-1369 AND
RP   ILE-1572.
RX   PubMed=8923011; DOI=10.1093/hmg/5.11.1813;
RA   Nestorowicz A., Wilson B.A., Schoor K.P., Inoue H., Glaser B.,
RA   Landau H., Stanley C.A., Thornton P.S., Clement J.P. IV, Bryan J.,
RA   Aguilar-Bryan L., Permutt M.A.;
RT   "Mutations in the sulfonylurea receptor gene are associated with
RT   familial hyperinsulinism in Ashkenazi Jews.";
RL   Hum. Mol. Genet. 5:1813-1822(1996).
RN   [13]
RP   CHARACTERIZATION OF VARIANT HHF1 ARG-1478.
RX   PubMed=8650576; DOI=10.1126/science.272.5269.1785;
RA   Nichols C.G., Shyng S.-L., Nestorowicz A., Glaser B., Clement J.P. IV,
RA   Gonzalez G., Aguilar-Bryan L., Permutt M.A., Bryan J.;
RT   "Adenosine diphosphate as an intracellular regulator of insulin
RT   secretion.";
RL   Science 272:1785-1787(1996).
RN   [14]
RP   VARIANTS GLN-275; MET-560; ASN-810; CYS-834 AND SER-1369.
RX   PubMed=9519757; DOI=10.2337/diabetes.47.3.476;
RA   Ohta Y., Tanizawa Y., Inoue H., Hosaka T., Ueda K., Matsutani A.,
RA   Repunte V.P., Yamada M., Kurachi Y., Bryan J., Aguilar-Bryan L.,
RA   Permutt M.A., Oka Y.;
RT   "Identification and functional analysis of sulfonylurea receptor 1
RT   variants in Japanese patients with NIDDM.";
RL   Diabetes 47:476-481(1998).
RN   [15]
RP   VARIANTS ASN-673 AND SER-1369.
RX   PubMed=9568693; DOI=10.2337/diabetes.47.4.598;
RA   Hansen T., Echwald S.M., Hansen L., Moeller A.M., Almind K.,
RA   Clausen J.O., Urhammer S.A., Inoue H., Ferrer J., Bryan J.,
RA   Aguilar-Bryan L., Permutt M.A., Pedersen O.;
RT   "Decreased tolbutamide-stimulated insulin secretion in healthy
RT   subjects with sequence variants in the high-affinity sulfonylurea
RT   receptor gene.";
RL   Diabetes 47:598-605(1998).
RN   [16]
RP   CHARACTERIZATION OF VARIANTS HHF1 GLN-125; SER-188; LEU-591; MET-1138;
RP   GLN-1214; SER-1381; PHE-1387 DEL AND HIS-1393.
RX   PubMed=9648840; DOI=10.2337/diabetes.47.7.1145;
RA   Shyng S.-L., Ferrigni T., Shepard J.B., Nestorowicz A., Glaser B.,
RA   Permutt M.A., Nichols C.G.;
RT   "Functional analyses of novel mutations in the sulfonylurea receptor 1
RT   associated with persistent hyperinsulinemic hypoglycemia of infancy.";
RL   Diabetes 47:1145-1151(1998).
RN   [17]
RP   VARIANTS HHF1 GLN-74; GLN-125; SER-188; ASP-406; LEU-591; MET-1138;
RP   GLN-1214; ARG-1378; SER-1381; PHE-1387 DEL AND HIS-1393.
RX   PubMed=9618169; DOI=10.1093/hmg/7.7.1119;
RA   Nestorowicz A., Glaser B., Wilson B.A., Shyng S.-L., Nichols C.G.,
RA   Stanley C.A., Thornton P.S., Permutt M.A.;
RT   "Genetic heterogeneity in familial hyperinsulinism.";
RL   Hum. Mol. Genet. 7:1119-1128(1998).
RN   [18]
RP   VARIANTS HHF1 PRO-1352; CYS-1420 AND TRP-1493.
RX   PubMed=9769320; DOI=10.1172/JCI4495;
RA   Verkarre V., Fournet J.-C., de Lonlay P., Gross-Morand M.-S.,
RA   Devillers M., Rahier J., Brunelle F., Robert J.-J., Nihoul-Fekete C.,
RA   Saudubray J.-M., Junien C.;
RT   "Paternal mutation of the sulfonylurea receptor (SUR1) gene and
RT   maternal loss of 11p15 imprinted genes lead to persistent
RT   hyperinsulinism in focal adenomatous hyperplasia.";
RL   J. Clin. Invest. 102:1286-1291(1998).
RN   [19]
RP   VARIANT HHF1 ASP-187.
RX   PubMed=10334322; DOI=10.2337/diabetes.48.2.408;
RA   Otonkoski T., Aemmaelae C., Huopio H., Cote G.J., Chapman J.,
RA   Cosgrove K., Ashfield R., Huang E., Komulainen J., Ashcroft F.M.,
RA   Dunne M.J., Kere J., Thomas P.M.;
RT   "A point mutation inactivating the sulfonylurea receptor causes the
RT   severe form of persistent hyperinsulinemic hypoglycemia of infancy in
RT   Finland.";
RL   Diabetes 48:408-415(1999).
RN   [20]
RP   VARIANTS SER-1369 AND ILE-1572.
RX   PubMed=10447255;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:1<23::AID-HUMU3>3.0.CO;2-#;
RA   Glaser B., Furth J., Stanley C.A., Baker L., Thornton P.S., Landau H.,
RA   Permutt M.A.;
RT   "Intragenic single nucleotide polymorphism haplotype analysis of SUR1
RT   mutations in familial hyperinsulinism.";
RL   Hum. Mutat. 14:23-29(1999).
RN   [21]
RP   VARIANTS HHF1 GLY-841; CYS-1420 AND TRP-1493.
RX   PubMed=10202168; DOI=10.1056/NEJM199904153401505;
RA   de Lonlay-Debeney P., Poggi-Travert F., Fournet J.-C., Sempoux C.,
RA   Vici C.D., Brunelle F., Touati G., Rahier J., Junien C.,
RA   Nihoul-Fekete C., Robert J.-J., Saudubray J.-M.;
RT   "Clinical features of 52 neonates with hyperinsulinism.";
RL   N. Engl. J. Med. 340:1169-1175(1999).
RN   [22]
RP   CHARACTERIZATION OF VARIANTS HHF1 CYS-1420 AND GLN-1436, AND VARIANT
RP   SER-1369.
RX   PubMed=10615958; DOI=10.2337/diabetes.49.1.114;
RA   Tanizawa Y., Matsuda K., Matsuo M., Ohta Y., Ochi N., Adachi M.,
RA   Koga M., Mizuno S., Kajita M., Tanaka Y., Tachibana K., Inoue H.,
RA   Furukawa S., Amachi T., Ueda K., Oka Y.;
RT   "Genetic analysis of Japanese patients with persistent
RT   hyperinsulinemic hypoglycemia of infancy: nucleotide-binding fold-2
RT   mutation impairs cooperative binding of adenine nucleotides to
RT   sulfonylurea receptor 1.";
RL   Diabetes 49:114-120(2000).
RN   [23]
RP   CHARACTERIZATION OF VARIANT HHF1 LYS-1506.
RX   PubMed=11018078; DOI=10.1172/JCI9804;
RA   Huopio H., Reimann F., Ashfield R., Komulainen J., Lenko H.-L.,
RA   Rahier J., Vauhkonen I., Kere J., Laakso M., Ashcroft F.,
RA   Otonkoski T.;
RT   "Dominantly inherited hyperinsulinism caused by a mutation in the
RT   sulfonylurea receptor type 1.";
RL   J. Clin. Invest. 106:897-906(2000).
RN   [24]
RP   CHARACTERIZATION OF VARIANT HHF1 PHE-1387 DEL.
RX   PubMed=11226335; DOI=10.1073/pnas.051499698;
RA   Cartier E.A., Conti L.R., Vandenberg C.A., Shyng S.-L.;
RT   "Defective trafficking and function of KATP channels caused by a
RT   sulfonylurea receptor 1 mutation associated with persistent
RT   hyperinsulinemic hypoglycemia of infancy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:2882-2887(2001).
RN   [25]
RP   CHARACTERIZATION OF VARIANT HHF1 PRO-1543.
RX   PubMed=11867634; DOI=10.1074/jbc.M200363200;
RA   Taschenberger G., Mougey A., Shen S., Lester L.B., LaFranchi S.,
RA   Shyng S.-L.;
RT   "Identification of a familial hyperinsulinism-causing mutation in the
RT   sulfonylurea receptor 1 that prevents normal trafficking and function
RT   of KATP channels.";
RL   J. Biol. Chem. 277:17139-17146(2002).
RN   [26]
RP   VARIANTS HHF1 ASP-187; THR-1457; LYS-1506; ASP-1550 AND VAL-1551.
RX   PubMed=12364426; DOI=10.1210/jc.2002-020378;
RA   Huopio H., Jaeaeskelaeinen J., Komulainen J., Miettinen R.,
RA   Kaerkkaeinen P., Laakso M., Tapanainen P., Voutilainen R.,
RA   Otonkoski T.;
RT   "Acute insulin response tests for the differential diagnosis of
RT   congenital hyperinsulinism.";
RL   J. Clin. Endocrinol. Metab. 87:4502-4507(2002).
RN   [27]
RP   VARIANT HHF1 SER-1385 DEL, AND CHARACTERIZATION OF VARIANT HHF1
RP   SER-1385 DEL.
RX   PubMed=12941782; DOI=10.2337/diabetes.52.9.2403;
RA   Thornton P.S., MacMullen C., Ganguly A., Ruchelli E., Steinkrauss L.,
RA   Crane A., Aguilar-Bryan L., Stanley C.A.;
RT   "Clinical and molecular characterization of a dominant form of
RT   congenital hyperinsulinism caused by a mutation in the high-affinity
RT   sulfonylurea receptor.";
RL   Diabetes 52:2403-2410(2003).
RN   [28]
RP   VARIANT LIH HIS-1352, AND CHARACTERIZATION OF VARIANT LIH HIS-1352.
RX   PubMed=15356046; DOI=10.1210/jc.2004-0441;
RA   Magge S.N., Shyng S.-L., MacMullen C., Steinkrauss L., Ganguly A.,
RA   Katz L.E.L., Stanley C.A.;
RT   "Familial leucine-sensitive hypoglycemia of infancy due to a dominant
RT   mutation of the beta-cell sulfonylurea receptor.";
RL   J. Clin. Endocrinol. Metab. 89:4450-4456(2004).
RN   [29]
RP   VARIANTS HHF1 GLU-70; ARG-111; GLU-1342; HIS-1418 AND TRP-1493, AND
RP   CHARACTERIZATION OF VARIANTS HHF1 GLU-70; ARG-111; GLU-1342; HIS-1418
RP   AND TRP-1493.
RX   PubMed=15579781; DOI=10.1210/jc.2004-1233;
RA   Tornovsky S., Crane A., Cosgrove K.E., Hussain K., Lavie J.,
RA   Heyman M., Nesher Y., Kuchinski N., Ben-Shushan E., Shatz O.,
RA   Nahari E., Potikha T., Zangen D., Tenenbaum-Rakover Y., de Vries L.,
RA   Argente J., Gracia R., Landau H., Eliakim A., Lindley K., Dunne M.J.,
RA   Aguilar-Bryan L., Glaser B.;
RT   "Hyperinsulinism of infancy: novel ABCC8 and KCNJ11 mutations and
RT   evidence for additional locus heterogeneity.";
RL   J. Clin. Endocrinol. Metab. 89:6224-6234(2004).
RN   [30]
RP   VARIANTS HHF1 GLN-1384 AND LYS-1486, AND VARIANT SER-1369.
RX   PubMed=15807877; DOI=10.1111/j.1365-2265.2005.02242.x;
RA   Ohkubo K., Nagashima M., Naito Y., Taguchi T., Suita S., Okamoto N.,
RA   Fujinaga H., Tsumura K., Kikuchi K., Ono J.;
RT   "Genotypes of the pancreatic beta-cell K-ATP channel and clinical
RT   phenotypes of Japanese patients with persistent hyperinsulinaemic
RT   hypoglycaemia of infancy.";
RL   Clin. Endocrinol. (Oxf.) 62:458-465(2005).
RN   [31]
RP   VARIANTS HHF1 SER-27; TRP-74; SER-188; GLN-495; LYS-501; SER-686;
RP   TRP-1214; GLN-1214; ASN-1336; PHE-1387 DEL; HIS-1471 AND ASN-1471.
RX   PubMed=15562009; DOI=10.1210/jc.2004-1604;
RA   Henwood M.J., Kelly A., MacMullen C., Bhatia P., Ganguly A.,
RA   Thornton P.S., Stanley C.A.;
RT   "Genotype-phenotype correlations in children with congenital
RT   hyperinsulinism due to recessive mutations of the adenosine
RT   triphosphate-sensitive potassium channel genes.";
RL   J. Clin. Endocrinol. Metab. 90:789-794(2005).
RN   [32]
RP   VARIANT PNDM LEU-132, AND CHARACTERIZATION OF VARIANT PNDM LEU-132.
RX   PubMed=16613899; DOI=10.1093/hmg/ddl101;
RA   Proks P., Arnold A.L., Bruining J., Girard C., Flanagan S.E.,
RA   Larkin B., Colclough K., Hattersley A.T., Ashcroft F.M., Ellard S.;
RT   "A heterozygous activating mutation in the sulphonylurea receptor SUR1
RT   (ABCC8) causes neonatal diabetes.";
RL   Hum. Mol. Genet. 15:1793-1800(2006).
RN   [33]
RP   VARIANTS HHF1 TRP-74; ARG-111; SER-188; ARG-233; ASN-310; ARG-551;
RP   THR-719; PRO-1130; ARG-1147; LYS-1295 AND PRO-1450, AND VARIANTS
RP   SER-1369 AND ILE-1572.
RX   PubMed=16429405; DOI=10.1002/humu.9401;
RA   Fernandez-Marmiesse A., Salas A., Vega A., Fernandez-Lorenzo J.R.,
RA   Barreiro J., Carracedo A.;
RT   "Mutation spectra of ABCC8 gene in Spanish patients with
RT   Hyperinsulinism of Infancy (HI).";
RL   Hum. Mutat. 27:214-214(2006).
RN   [34]
RP   VARIANTS HHF1 ARG-7; ASP-21; SER-27; TRP-74; LYS-501; PRO-503;
RP   SER-686; TRP-1214; TRP-1214; GLN-1349; ARG-1378; PHE-1387 DEL;
RP   ARG-1400 AND GLN-1493.
RX   PubMed=16357843; DOI=10.1038/modpathol.3800497;
RA   Suchi M., MacMullen C.M., Thornton P.S., Adzick N.S., Ganguly A.,
RA   Ruchelli E.D., Stanley C.A.;
RT   "Molecular and immunohistochemical analyses of the focal form of
RT   congenital hyperinsulinism.";
RL   Mod. Pathol. 19:122-129(2006).
RN   [35]
RP   VARIANTS PNDM ARG-213 AND VAL-1424, VARIANTS TNDM2 ARG-435; VAL-582;
RP   TYR-1023; GLN-1182 AND CYS-1379, CHARACTERIZATION OF VARIANT PNDM
RP   VAL-1424, AND CHARACTERIZATION OF VARIANT TNDM2 TYR-1023.
RX   PubMed=16885549; DOI=10.1056/NEJMoa055068;
RA   Babenko A.P., Polak M., Cave H., Busiah K., Czernichow P.,
RA   Scharfmann R., Bryan J., Aguilar-Bryan L., Vaxillaire M., Froguel P.;
RT   "Activating mutations in the ABCC8 gene in neonatal diabetes
RT   mellitus.";
RL   N. Engl. J. Med. 355:456-466(2006).
RN   [36]
RP   VARIANTS PNDM LEU-45; SER-72; ALA-86; GLY-86; LEU-132; VAL-132;
RP   SER-207; LYS-208; GLU-209; LYS-211; PRO-225; ILE-229; ASP-263;
RP   LYS-382; GLU-1184; LYS-1326; ARG-1400 AND LEU-1522, AND
RP   CHARACTERIZATION OF VARIANTS PNDM LEU-132; SER-207; ILE-229; GLU-1184
RP   AND LEU-1522.
RX   PubMed=17668386; DOI=10.1086/519174;
RA   Ellard S., Flanagan S.E., Girard C.A., Patch A.M., Harries L.W.,
RA   Parrish A., Edghill E.L., Mackay D.J., Proks P., Shimomura K.,
RA   Haberland H., Carson D.J., Shield J.P., Hattersley A.T.,
RA   Ashcroft F.M.;
RT   "Permanent neonatal diabetes caused by dominant, recessive, or
RT   compound heterozygous SUR1 mutations with opposite functional
RT   effects.";
RL   Am. J. Hum. Genet. 81:375-382(2007).
RN   [37]
RP   VARIANT PNDM ALA-86.
RX   PubMed=17213273; DOI=10.1210/jc.2006-2490;
RA   Stanik J., Gasperikova D., Paskova M., Barak L., Javorkova J.,
RA   Jancova E., Ciljakova M., Hlava P., Michalek J., Flanagan S.E.,
RA   Pearson E., Hattersley A.T., Ellard S., Klimes I.;
RT   "Prevalence of permanent neonatal diabetes in Slovakia and successful
RT   replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8
RT   mutation carriers.";
RL   J. Clin. Endocrinol. Metab. 92:1276-1282(2007).
RN   [38]
RP   VARIANTS HHF1 MET-511; ASP-716; LYS-824; THR-889; PRO-890; PRO-1352;
RP   SER-1378; PHE-1386; TYR-1388; PRO-1389; VAL-1457; ILE-1480; GLU-1505
RP   AND SER-1511, CHARACTERIZATION OF VARIANTS HHF1 MET-511; LYS-824;
RP   THR-889; PRO-890; SER-1378; VAL-1457; ILE-1480; GLU-1505 AND SER-1511,
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=24814349; DOI=10.1111/cge.12428;
RA   Saint-Martin C., Zhou Q., Martin G.M., Vaury C., Leroy G.,
RA   Arnoux J.B., de Lonlay P., Shyng S.L., Bellanne-Chantelot C.;
RT   "Monoallelic ABCC8 mutations are a common cause of diazoxide-
RT   unresponsive diffuse form of congenital hyperinsulinism.";
RL   Clin. Genet. 87:448-454(2015).
RN   [39]
RP   VARIANT HHF1 HIS-1418, CHARACTERIZATION OF VARIANT HHF1 HIS-1418, AND
RP   FUNCTION.
RX   PubMed=25720052; DOI=10.1515/jpem-2014-0265;
RA   Harel S., Cohen A.S., Hussain K., Flanagan S.E., Schlade-Bartusiak K.,
RA   Patel M., Courtade J., Li J.B., Van Karnebeek C., Kurata H.,
RA   Ellard S., Chanoine J.P., Gibson W.T.;
RT   "Alternating hypoglycemia and hyperglycemia in a toddler with a
RT   homozygous p.R1419H ABCC8 mutation: an unusual clinical picture.";
RL   J. Pediatr. Endocrinol. Metab. 28:345-351(2015).
CC   -!- FUNCTION: Subunit of the beta-cell ATP-sensitive potassium channel
CC       (KATP). Regulator of ATP-sensitive K(+) channels and insulin
CC       release. {ECO:0000269|PubMed:24814349,
CC       ECO:0000269|PubMed:25720052}.
CC   -!- SUBUNIT: Interacts with KCNJ11.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:24814349};
CC       Multi-pass membrane protein {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q09428-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q09428-2; Sequence=VSP_000055;
CC       Name=3; Synonyms=SUR1Delta2;
CC         IsoId=Q09428-3; Sequence=VSP_044090;
CC         Note=Abundant isoform with prodiabetic properties, predominant
CC         in heart.;
CC   -!- DISEASE: Leucine-induced hypoglycemia (LIH) [MIM:240800]: Rare
CC       cause of hypoglycemia and is described as a condition in which
CC       symptomatic hypoglycemia is provoked by high protein feedings.
CC       Hypoglycemia is also elicited by administration of oral or
CC       intravenous infusions of a single amino acid, leucine.
CC       {ECO:0000269|PubMed:15356046}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Familial hyperinsulinemic hypoglycemia 1 (HHF1)
CC       [MIM:256450]: Most common cause of persistent hypoglycemia in
CC       infancy. Unless early and aggressive intervention is undertaken,
CC       brain damage from recurrent episodes of hypoglycemia may occur.
CC       {ECO:0000269|PubMed:10202168, ECO:0000269|PubMed:10334322,
CC       ECO:0000269|PubMed:10615958, ECO:0000269|PubMed:11018078,
CC       ECO:0000269|PubMed:11226335, ECO:0000269|PubMed:11867634,
CC       ECO:0000269|PubMed:12364426, ECO:0000269|PubMed:12941782,
CC       ECO:0000269|PubMed:15562009, ECO:0000269|PubMed:15579781,
CC       ECO:0000269|PubMed:15807877, ECO:0000269|PubMed:16357843,
CC       ECO:0000269|PubMed:16429405, ECO:0000269|PubMed:24814349,
CC       ECO:0000269|PubMed:25720052, ECO:0000269|PubMed:8650576,
CC       ECO:0000269|PubMed:8751851, ECO:0000269|PubMed:8923011,
CC       ECO:0000269|PubMed:9618169, ECO:0000269|PubMed:9648840,
CC       ECO:0000269|PubMed:9769320}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Diabetes mellitus, permanent neonatal (PNDM)
CC       [MIM:606176]: A rare form of diabetes distinct from childhood-
CC       onset autoimmune diabetes mellitus type 1. It is characterized by
CC       insulin-requiring hyperglycemia that is diagnosed within the first
CC       months of life. Permanent neonatal diabetes requires lifelong
CC       therapy. {ECO:0000269|PubMed:16613899,
CC       ECO:0000269|PubMed:16885549, ECO:0000269|PubMed:17213273,
CC       ECO:0000269|PubMed:17668386}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Transient neonatal diabetes mellitus 2 (TNDM2)
CC       [MIM:610374]: Neonatal diabetes is a form of diabetes mellitus
CC       defined by the onset of mild-to-severe hyperglycemia within the
CC       first months of life. Transient neonatal diabetes remits early,
CC       with a possible relapse during adolescence.
CC       {ECO:0000269|PubMed:16885549}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. ABCC
CC       family. Conjugate transporter (TC 3.A.1.208) subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=ABCMdb; Note=Database for mutations in ABC
CC       proteins;
CC       URL="http://abcmutations.hegelab.org/proteinDetails?uniprot_id=Q09428";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; HM635782; ADM67556.1; -; mRNA.
DR   EMBL; L78207; AAB02278.1; -; mRNA.
DR   EMBL; L78243; AAB02417.1; -; Genomic_DNA.
DR   EMBL; L78208; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78209; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78210; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78211; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78212; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78255; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78213; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78214; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78215; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78216; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78217; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78218; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78219; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78220; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78221; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78222; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78223; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78225; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78254; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78226; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78227; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78228; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78229; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78230; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78231; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78232; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78233; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78234; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78235; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78236; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78237; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78238; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78239; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78240; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78241; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78242; AAB02417.1; JOINED; Genomic_DNA.
DR   EMBL; L78243; AAB02418.1; -; Genomic_DNA.
DR   EMBL; L78208; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78209; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78210; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78211; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78212; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78255; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78213; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78214; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78215; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78216; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78217; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78218; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78219; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78220; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78221; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78222; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78224; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78225; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78254; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78226; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78227; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78228; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78229; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78230; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78231; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78232; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78233; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78234; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78235; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78236; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78237; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78238; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78239; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78240; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78241; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; L78242; AAB02418.1; JOINED; Genomic_DNA.
DR   EMBL; U63421; AAB36699.1; -; mRNA.
DR   EMBL; U63455; AAB36700.1; -; Genomic_DNA.
DR   EMBL; U63422; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63423; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63424; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63425; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63426; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63427; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63428; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63429; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63430; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63431; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63432; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63433; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63434; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63435; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63436; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63437; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63438; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63439; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63441; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63442; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63443; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63444; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63445; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63446; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63447; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63448; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63449; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63450; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63451; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63452; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63453; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; U63454; AAB36700.1; JOINED; Genomic_DNA.
DR   EMBL; AF087138; AAC36724.1; -; mRNA.
DR   EMBL; AC124798; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L40625; AAA99227.1; -; mRNA.
DR   CCDS; CCDS31437.1; -. [Q09428-1]
DR   CCDS; CCDS73264.1; -. [Q09428-2]
DR   RefSeq; NP_000343.2; NM_000352.4. [Q09428-1]
DR   RefSeq; NP_001274103.1; NM_001287174.1. [Q09428-2]
DR   UniGene; Hs.54470; -.
DR   ProteinModelPortal; Q09428; -.
DR   BioGrid; 112700; 2.
DR   DIP; DIP-58642N; -.
DR   STRING; 9606.ENSP00000374467; -.
DR   BindingDB; Q09428; -.
DR   ChEMBL; CHEMBL2071; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB00672; Chlorpropamide.
DR   DrugBank; DB01120; Gliclazide.
DR   DrugBank; DB00222; Glimepiride.
DR   DrugBank; DB01067; Glipizide.
DR   DrugBank; DB01251; Gliquidone.
DR   DrugBank; DB01016; Glyburide.
DR   DrugBank; DB01382; Glycodiazine.
DR   DrugBank; DB01252; Mitiglinide.
DR   DrugBank; DB00731; Nateglinide.
DR   DrugBank; DB00912; Repaglinide.
DR   DrugBank; DB01124; Tolbutamide.
DR   GuidetoPHARMACOLOGY; 2594; -.
DR   TCDB; 3.A.1.208.4; the atp-binding cassette (abc) superfamily.
DR   iPTMnet; Q09428; -.
DR   PhosphoSitePlus; Q09428; -.
DR   BioMuta; ABCC8; -.
DR   DMDM; 311033501; -.
DR   EPD; Q09428; -.
DR   PaxDb; Q09428; -.
DR   PeptideAtlas; Q09428; -.
DR   PRIDE; Q09428; -.
DR   DNASU; 6833; -.
DR   Ensembl; ENST00000302539; ENSP00000303960; ENSG00000006071. [Q09428-2]
DR   Ensembl; ENST00000389817; ENSP00000374467; ENSG00000006071. [Q09428-1]
DR   Ensembl; ENST00000612903; ENSP00000483031; ENSG00000006071. [Q09428-3]
DR   GeneID; 6833; -.
DR   KEGG; hsa:6833; -.
DR   UCSC; uc001mnc.4; human. [Q09428-1]
DR   CTD; 6833; -.
DR   DisGeNET; 6833; -.
DR   GeneCards; ABCC8; -.
DR   GeneReviews; ABCC8; -.
DR   H-InvDB; HIX0035864; -.
DR   HGNC; HGNC:59; ABCC8.
DR   HPA; CAB011451; -.
DR   HPA; HPA042318; -.
DR   MalaCards; ABCC8; -.
DR   MIM; 240800; phenotype.
DR   MIM; 256450; phenotype.
DR   MIM; 600509; gene.
DR   MIM; 602485; phenotype.
DR   MIM; 606176; phenotype.
DR   MIM; 610374; phenotype.
DR   neXtProt; NX_Q09428; -.
DR   OpenTargets; ENSG00000006071; -.
DR   Orphanet; 276575; Autosomal dominant hyperinsulinism due to SUR1 deficiency.
DR   Orphanet; 79643; Autosomal recessive hyperinsulinism due to SUR1 deficiency.
DR   Orphanet; 79134; DEND syndrome.
DR   Orphanet; 276598; Diazoxide-resistant focal hyperinsulinism due to SUR1 deficiency.
DR   Orphanet; 552; MODY.
DR   Orphanet; 99885; Permanent neonatal diabetes mellitus.
DR   Orphanet; 99886; Transient neonatal diabetes mellitus.
DR   PharmGKB; PA24395; -.
DR   eggNOG; KOG0054; Eukaryota.
DR   eggNOG; COG1132; LUCA.
DR   GeneTree; ENSGT00870000136472; -.
DR   HOVERGEN; HBG101342; -.
DR   InParanoid; Q09428; -.
DR   KO; K05032; -.
DR   OMA; QGQASKY; -.
DR   OrthoDB; EOG091G00IN; -.
DR   PhylomeDB; Q09428; -.
DR   TreeFam; TF105201; -.
DR   Reactome; R-HSA-1296025; ATP sensitive Potassium channels.
DR   Reactome; R-HSA-382556; ABC-family proteins mediated transport.
DR   Reactome; R-HSA-422356; Regulation of insulin secretion.
DR   Reactome; R-HSA-5683177; Defective ABCC8 can cause hypoglycemias and hyperglycemias.
DR   SignaLink; Q09428; -.
DR   ChiTaRS; ABCC8; human.
DR   GeneWiki; ABCC8; -.
DR   GenomeRNAi; 6833; -.
DR   PRO; PR:Q09428; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000006071; -.
DR   CleanEx; HS_ABCC8; -.
DR   ExpressionAtlas; Q09428; baseline and differential.
DR   Genevisible; Q09428; HS.
DR   GO; GO:0008282; C:ATP-sensitive potassium channel complex; IBA:GO_Central.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0042383; C:sarcolemma; IBA:GO_Central.
DR   GO; GO:0030672; C:synaptic vesicle membrane; IEA:Ensembl.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0015272; F:ATP-activated inward rectifier potassium channel activity; TAS:Reactome.
DR   GO; GO:0042626; F:ATPase activity, coupled to transmembrane movement of substances; IBA:GO_Central.
DR   GO; GO:0043225; F:ATPase-coupled anion transmembrane transporter activity; TAS:Reactome.
DR   GO; GO:0044325; F:ion channel binding; IPI:BHF-UCL.
DR   GO; GO:0005267; F:potassium channel activity; IMP:UniProtKB.
DR   GO; GO:0008281; F:sulfonylurea receptor activity; IEA:InterPro.
DR   GO; GO:0019905; F:syntaxin binding; IEA:Ensembl.
DR   GO; GO:0071310; P:cellular response to organic substance; IEA:Ensembl.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0060253; P:negative regulation of glial cell proliferation; IEA:Ensembl.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0097402; P:neuroblast migration; IEA:Ensembl.
DR   GO; GO:1905605; P:positive regulation of maintenance of permeability of blood-brain barrier; IEA:Ensembl.
DR   GO; GO:1904469; P:positive regulation of tumor necrosis factor secretion; IEA:Ensembl.
DR   GO; GO:1900721; P:positive regulation of uterine smooth muscle relaxation; IEA:Ensembl.
DR   GO; GO:1903818; P:positive regulation of voltage-gated potassium channel activity; IEA:Ensembl.
DR   GO; GO:0006813; P:potassium ion transport; TAS:ProtInc.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:Reactome.
DR   GO; GO:0042493; P:response to drug; IBA:GO_Central.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0009268; P:response to pH; IEA:Ensembl.
DR   GO; GO:0010043; P:response to zinc ion; IEA:Ensembl.
DR   GO; GO:0055085; P:transmembrane transport; TAS:Reactome.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011527; ABC1_TM_dom.
DR   InterPro; IPR003439; ABC_transporter-like.
DR   InterPro; IPR017871; ABC_transporter_CS.
DR   InterPro; IPR000844; ABCC8.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000388; Sulphorea_rcpt.
DR   PANTHER; PTHR24223:SF293; PTHR24223:SF293; 1.
DR   Pfam; PF00664; ABC_membrane; 2.
DR   Pfam; PF00005; ABC_tran; 2.
DR   PRINTS; PR01093; SULFNYLUR1.
DR   PRINTS; PR01092; SULFNYLUREAR.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   SUPFAM; SSF90123; SSF90123; 2.
DR   PROSITE; PS50929; ABC_TM1F; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Complete proteome;
KW   Diabetes mellitus; Disease mutation; Glycoprotein; Membrane;
KW   Nucleotide-binding; Polymorphism; Receptor; Reference proteome;
KW   Repeat; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1   1581       ATP-binding cassette sub-family C member
FT                                8.
FT                                /FTId=PRO_0000093400.
FT   TOPO_DOM      1     34       Extracellular. {ECO:0000250}.
FT   TRANSMEM     35     55       Helical; Name=1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM     56     75       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM     76     96       Helical; Name=2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM     97    101       Extracellular. {ECO:0000250}.
FT   TRANSMEM    102    122       Helical; Name=3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    123    134       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM    135    154       Helical; Name=4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    155    167       Extracellular. {ECO:0000250}.
FT   TRANSMEM    168    194       Helical; Name=5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    195    311       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM    312    331       Helical; Name=6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    332    355       Extracellular. {ECO:0000250}.
FT   TRANSMEM    356    376       Helical; Name=7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    377    434       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM    435    455       Helical; Name=8. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    456    458       Extracellular. {ECO:0000250}.
FT   TRANSMEM    459    479       Helical; Name=9. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    480    541       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM    542    562       Helical; Name=10. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    563    584       Extracellular. {ECO:0000250}.
FT   TRANSMEM    585    605       Helical; Name=11. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM    606   1004       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM   1005   1025       Helical; Name=12. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM   1026   1072       Extracellular. {ECO:0000250}.
FT   TRANSMEM   1073   1093       Helical; Name=13. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM   1094   1137       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM   1138   1158       Helical; Name=14. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM   1159   1159       Extracellular. {ECO:0000250}.
FT   TRANSMEM   1160   1180       Helical; Name=15. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM   1181   1251       Cytoplasmic. {ECO:0000250}.
FT   TRANSMEM   1252   1272       Helical; Name=16. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM   1273   1276       Extracellular. {ECO:0000250}.
FT   TRANSMEM   1277   1297       Helical; Name=17. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00441}.
FT   TOPO_DOM   1298   1581       Cytoplasmic. {ECO:0000250}.
FT   DOMAIN      299    602       ABC transmembrane type-1 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00441}.
FT   DOMAIN      679    929       ABC transporter 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   DOMAIN     1012   1306       ABC transmembrane type-1 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00441}.
FT   DOMAIN     1344   1578       ABC transporter 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   NP_BIND     713    720       ATP 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   NP_BIND    1378   1385       ATP 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00434}.
FT   CARBOHYD     10     10       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000250}.
FT   CARBOHYD   1049   1049       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000250}.
FT   VAR_SEQ      51   1581       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:21671119}.
FT                                /FTId=VSP_044090.
FT   VAR_SEQ     740    740       S -> SS (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_000055.
FT   VARIANT       7      7       G -> R (in HHF1).
FT                                {ECO:0000269|PubMed:16357843}.
FT                                /FTId=VAR_031349.
FT   VARIANT      21     21       V -> D (in HHF1; dbSNP:rs200670692).
FT                                {ECO:0000269|PubMed:16357843}.
FT                                /FTId=VAR_031350.
FT   VARIANT      27     27       F -> S (in HHF1).
FT                                {ECO:0000269|PubMed:15562009,
FT                                ECO:0000269|PubMed:16357843}.
FT                                /FTId=VAR_031351.
FT   VARIANT      45     45       P -> L (in PNDM; compound heterozygous
FT                                with R-1400; dbSNP:rs267606623).
FT                                {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072928.
FT   VARIANT      70     70       G -> E (in HHF1; altered intracellular
FT                                trafficking).
FT                                {ECO:0000269|PubMed:15579781}.
FT                                /FTId=VAR_031352.
FT   VARIANT      72     72       N -> S (in PNDM; mosaic;
FT                                dbSNP:rs80356634).
FT                                {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072929.
FT   VARIANT      74     74       R -> Q (in HHF1; dbSNP:rs72559734).
FT                                {ECO:0000269|PubMed:9618169}.
FT                                /FTId=VAR_008639.
FT   VARIANT      74     74       R -> W (in HHF1; dbSNP:rs201682634).
FT                                {ECO:0000269|PubMed:15562009,
FT                                ECO:0000269|PubMed:16357843,
FT                                ECO:0000269|PubMed:16429405}.
FT                                /FTId=VAR_031353.
FT   VARIANT      86     86       V -> A (in PNDM; dbSNP:rs193929360).
FT                                {ECO:0000269|PubMed:17213273,
FT                                ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_031354.
FT   VARIANT      86     86       V -> G (in PNDM; dbSNP:rs193929360).
FT                                {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072930.
FT   VARIANT     104    104       L -> V (in dbSNP:rs10400391).
FT                                /FTId=VAR_029777.
FT   VARIANT     111    111       G -> R (in HHF1; altered intracellular
FT                                trafficking; dbSNP:rs761749884).
FT                                {ECO:0000269|PubMed:15579781,
FT                                ECO:0000269|PubMed:16429405}.
FT                                /FTId=VAR_031355.
FT   VARIANT     116    116       A -> P (in HHF1; dbSNP:rs72559731).
FT                                /FTId=VAR_031356.
FT   VARIANT     125    125       H -> Q (in HHF1; mild; dbSNP:rs60637558).
FT                                {ECO:0000269|PubMed:9618169,
FT                                ECO:0000269|PubMed:9648840}.
FT                                /FTId=VAR_008640.
FT   VARIANT     132    132       F -> L (in PNDM; with neurologic
FT                                features; reduces the sensitivity of the
FT                                K(ATP) channel to inhibition by MgATP;
FT                                increases whole-cell K(ATP) current;
FT                                dbSNP:rs80356637).
FT                                {ECO:0000269|PubMed:16613899,
FT                                ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_029778.
FT   VARIANT     132    132       F -> V (in PNDM; dbSNP:rs80356637).
FT                                {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072931.
FT   VARIANT     187    187       V -> D (in HHF1; severe; high prevalence
FT                                in Finland; loss of channel activity;
FT                                dbSNP:rs137852672).
FT                                {ECO:0000269|PubMed:10334322,
FT                                ECO:0000269|PubMed:12364426}.
FT                                /FTId=VAR_008641.
FT   VARIANT     188    188       N -> S (in HHF1; severe;
FT                                dbSNP:rs797045213).
FT                                {ECO:0000269|PubMed:15562009,
FT                                ECO:0000269|PubMed:16429405,
FT                                ECO:0000269|PubMed:9618169,
FT                                ECO:0000269|PubMed:9648840}.
FT                                /FTId=VAR_008642.
FT   VARIANT     207    207       P -> S (in PNDM; reduced inhibition by
FT                                ATP). {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072932.
FT   VARIANT     208    208       E -> K (in PNDM; compound heterozygous
FT                                with D-263).
FT                                {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072933.
FT   VARIANT     209    209       D -> E (in PNDM; dbSNP:rs80356640).
FT                                {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072934.
FT   VARIANT     211    211       Q -> K (in PNDM; dbSNP:rs193929366).
FT                                {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072935.
FT   VARIANT     213    213       L -> R (in PNDM; dbSNP:rs80356642).
FT                                {ECO:0000269|PubMed:16885549}.
FT                                /FTId=VAR_029779.
FT   VARIANT     225    225       L -> P (in PNDM; dbSNP:rs1048095).
FT                                {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072936.
FT   VARIANT     229    229       T -> I (in PNDM; compound heterozygous
FT                                with L-1523; highly reduced inhibition by
FT                                ATP when associated with L-1523;
FT                                dbSNP:rs768017509).
FT                                {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072937.
FT   VARIANT     233    233       M -> R (in HHF1).
FT                                {ECO:0000269|PubMed:16429405}.
FT                                /FTId=VAR_031357.
FT   VARIANT     263    263       Y -> D (in PNDM; compound heterozygous
FT                                with K-208; dbSNP:rs778892038).
FT                                {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072938.
FT   VARIANT     275    275       R -> Q (in dbSNP:rs185040406).
FT                                {ECO:0000269|PubMed:9519757}.
FT                                /FTId=VAR_008643.
FT   VARIANT     310    310       D -> N (in HHF1; dbSNP:rs769569410).
FT                                {ECO:0000269|PubMed:16429405}.
FT                                /FTId=VAR_031358.
FT   VARIANT     382    382       E -> K (in PNDM; dbSNP:rs80356651).
FT                                {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072939.
FT   VARIANT     406    406       N -> D (in HHF1; dbSNP:rs72559728).
FT                                {ECO:0000269|PubMed:9618169}.
FT                                /FTId=VAR_008644.
FT   VARIANT     418    418       C -> R (in HHF1; dbSNP:rs67254669).
FT                                /FTId=VAR_031359.
FT   VARIANT     435    435       C -> R (in TNDM2).
FT                                {ECO:0000269|PubMed:16885549}.
FT                                /FTId=VAR_029780.
FT   VARIANT     495    495       R -> Q (in HHF1).
FT                                {ECO:0000269|PubMed:15562009}.
FT                                /FTId=VAR_031360.
FT   VARIANT     501    501       E -> K (in HHF1; dbSNP:rs372307320).
FT                                {ECO:0000269|PubMed:15562009,
FT                                ECO:0000269|PubMed:16357843}.
FT                                /FTId=VAR_031361.
FT   VARIANT     503    503       L -> P (in HHF1).
FT                                {ECO:0000269|PubMed:16357843}.
FT                                /FTId=VAR_031362.
FT   VARIANT     508    508       L -> P (in HHF1; dbSNP:rs72559727).
FT                                /FTId=VAR_031363.
FT   VARIANT     511    511       L -> M (in HHF1; no effect on cell
FT                                membrane expression; no effect on traffic
FT                                efficiency; dramatically reduced
FT                                potassium channel response to activators
FT                                such as MgADP or to diazoxide).
FT                                {ECO:0000269|PubMed:24814349}.
FT                                /FTId=VAR_072940.
FT   VARIANT     551    551       P -> R (in HHF1).
FT                                {ECO:0000269|PubMed:16429405}.
FT                                /FTId=VAR_031364.
FT   VARIANT     560    560       V -> M (in dbSNP:rs4148619).
FT                                {ECO:0000269|PubMed:9519757}.
FT                                /FTId=VAR_008645.
FT   VARIANT     582    582       L -> V (in TNDM2; dbSNP:rs137852674).
FT                                {ECO:0000269|PubMed:16885549}.
FT                                /FTId=VAR_029781.
FT   VARIANT     591    591       F -> L (in HHF1; dbSNP:rs72559726).
FT                                {ECO:0000269|PubMed:9618169,
FT                                ECO:0000269|PubMed:9648840}.
FT                                /FTId=VAR_008646.
FT   VARIANT     620    620       R -> C (in HHF1; dbSNP:rs58241708).
FT                                /FTId=VAR_031365.
FT   VARIANT     673    673       D -> N (in dbSNP:rs777986828).
FT                                {ECO:0000269|PubMed:9568693}.
FT                                /FTId=VAR_015006.
FT   VARIANT     686    686       F -> S (in HHF1).
FT                                {ECO:0000269|PubMed:15562009,
FT                                ECO:0000269|PubMed:16357843}.
FT                                /FTId=VAR_031366.
FT   VARIANT     716    716       G -> D (in HHF1).
FT                                {ECO:0000269|PubMed:24814349}.
FT                                /FTId=VAR_072941.
FT   VARIANT     716    716       G -> V (in HHF1; dbSNP:rs72559723).
FT                                {ECO:0000269|PubMed:8751851}.
FT                                /FTId=VAR_000100.
FT   VARIANT     719    719       K -> T (in HHF1).
FT                                {ECO:0000269|PubMed:16429405}.
FT                                /FTId=VAR_031367.
FT   VARIANT     810    810       D -> N (in dbSNP:rs767572066).
FT                                {ECO:0000269|PubMed:9519757}.
FT                                /FTId=VAR_008647.
FT   VARIANT     824    824       E -> K (in HHF1; no effect on cell
FT                                membrane expression; no effect on traffic
FT                                efficiency; dramatically reduced
FT                                potassium channel response to activators
FT                                such as MgADP or to diazoxide).
FT                                {ECO:0000269|PubMed:24814349}.
FT                                /FTId=VAR_072942.
FT   VARIANT     834    834       R -> C (in dbSNP:rs140068774).
FT                                {ECO:0000269|PubMed:9519757}.
FT                                /FTId=VAR_008648.
FT   VARIANT     841    841       R -> G (in HHF1).
FT                                {ECO:0000269|PubMed:10202168}.
FT                                /FTId=VAR_031368.
FT   VARIANT     889    889       K -> T (in HHF1; no effect on cell
FT                                membrane expression; no effect on traffic
FT                                efficiency; reduced potassium channel
FT                                response to activators such as MgADP or
FT                                to diazoxide; dbSNP:rs761862121).
FT                                {ECO:0000269|PubMed:24814349}.
FT                                /FTId=VAR_031369.
FT   VARIANT     890    890       L -> P (in HHF1; no effect on cell
FT                                membrane expression; no effect on traffic
FT                                efficiency; dramatically reduced
FT                                potassium channel response to activators
FT                                such as MgADP or to diazoxide).
FT                                {ECO:0000269|PubMed:24814349}.
FT                                /FTId=VAR_072943.
FT   VARIANT     956    956       S -> F (in HHF1; dbSNP:rs72559721).
FT                                /FTId=VAR_031370.
FT   VARIANT    1023   1023       H -> Y (in TNDM2; overactive channel).
FT                                {ECO:0000269|PubMed:16885549}.
FT                                /FTId=VAR_029782.
FT   VARIANT    1130   1130       T -> P (in HHF1).
FT                                {ECO:0000269|PubMed:16429405}.
FT                                /FTId=VAR_031371.
FT   VARIANT    1138   1138       T -> M (in HHF1; dbSNP:rs201351976).
FT                                {ECO:0000269|PubMed:9618169,
FT                                ECO:0000269|PubMed:9648840}.
FT                                /FTId=VAR_008649.
FT   VARIANT    1147   1147       L -> R (in HHF1).
FT                                {ECO:0000269|PubMed:16429405}.
FT                                /FTId=VAR_031372.
FT   VARIANT    1182   1182       R -> Q (in TNDM2; dbSNP:rs193922400).
FT                                {ECO:0000269|PubMed:16885549}.
FT                                /FTId=VAR_029783.
FT   VARIANT    1184   1184       A -> E (in PNDM; slightly reduced
FT                                inhibition by ATP; dbSNP:rs137852675).
FT                                {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072944.
FT   VARIANT    1214   1214       R -> Q (in HHF1; severe;
FT                                dbSNP:rs367850779).
FT                                {ECO:0000269|PubMed:15562009,
FT                                ECO:0000269|PubMed:9618169,
FT                                ECO:0000269|PubMed:9648840}.
FT                                /FTId=VAR_008650.
FT   VARIANT    1214   1214       R -> W (in HHF1; dbSNP:rs139964066).
FT                                {ECO:0000269|PubMed:15562009,
FT                                ECO:0000269|PubMed:16357843}.
FT                                /FTId=VAR_031373.
FT   VARIANT    1295   1295       N -> K (in HHF1).
FT                                {ECO:0000269|PubMed:16429405}.
FT                                /FTId=VAR_031374.
FT   VARIANT    1326   1326       E -> K (in PNDM; dbSNP:rs200563930).
FT                                {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072945.
FT   VARIANT    1336   1336       K -> N (in HHF1; dbSNP:rs67767715).
FT                                {ECO:0000269|PubMed:15562009}.
FT                                /FTId=VAR_031375.
FT   VARIANT    1342   1342       G -> E (in HHF1; altered intracellular
FT                                trafficking).
FT                                {ECO:0000269|PubMed:15579781}.
FT                                /FTId=VAR_031376.
FT   VARIANT    1349   1349       L -> Q (in HHF1).
FT                                {ECO:0000269|PubMed:16357843}.
FT                                /FTId=VAR_031377.
FT   VARIANT    1352   1352       R -> H (in LIH; partially impairs ATP-
FT                                dependent potassium channel function;
FT                                dbSNP:rs28936370).
FT                                {ECO:0000269|PubMed:15356046}.
FT                                /FTId=VAR_029784.
FT   VARIANT    1352   1352       R -> P (in HHF1; dbSNP:rs28936370).
FT                                {ECO:0000269|PubMed:24814349,
FT                                ECO:0000269|PubMed:9769320}.
FT                                /FTId=VAR_008537.
FT   VARIANT    1360   1360       V -> G. {ECO:0000269|PubMed:8923011}.
FT                                /FTId=VAR_008651.
FT   VARIANT    1360   1360       V -> M (in HHF1).
FT                                /FTId=VAR_015007.
FT   VARIANT    1369   1369       A -> S (in dbSNP:rs757110).
FT                                {ECO:0000269|PubMed:10447255,
FT                                ECO:0000269|PubMed:10615958,
FT                                ECO:0000269|PubMed:15807877,
FT                                ECO:0000269|PubMed:16429405,
FT                                ECO:0000269|PubMed:7716548,
FT                                ECO:0000269|PubMed:8635661,
FT                                ECO:0000269|PubMed:8923011,
FT                                ECO:0000269|PubMed:9519757,
FT                                ECO:0000269|PubMed:9568693,
FT                                ECO:0000269|Ref.2, ECO:0000269|Ref.3,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_008652.
FT   VARIANT    1378   1378       G -> R (in HHF1).
FT                                {ECO:0000269|PubMed:16357843,
FT                                ECO:0000269|PubMed:9618169}.
FT                                /FTId=VAR_008653.
FT   VARIANT    1378   1378       G -> S (in HHF1; highly decreases cell
FT                                membrane expression; highly reduced
FT                                traffic efficiency; dramatically reduced
FT                                potassium channel response to activators
FT                                such as MgADP or to diazoxide).
FT                                {ECO:0000269|PubMed:24814349}.
FT                                /FTId=VAR_072946.
FT   VARIANT    1379   1379       R -> C (in TNDM2; dbSNP:rs137852673).
FT                                {ECO:0000269|PubMed:16885549}.
FT                                /FTId=VAR_029785.
FT   VARIANT    1381   1381       G -> S (in HHF1; dbSNP:rs773448052).
FT                                {ECO:0000269|PubMed:9618169,
FT                                ECO:0000269|PubMed:9648840}.
FT                                /FTId=VAR_008654.
FT   VARIANT    1384   1384       K -> Q (in HHF1).
FT                                {ECO:0000269|PubMed:15807877}.
FT                                /FTId=VAR_031378.
FT   VARIANT    1385   1385       Missing (in HHF1; does not alter surface
FT                                expression but channels are not
FT                                functional).
FT                                {ECO:0000269|PubMed:12941782}.
FT                                /FTId=VAR_029786.
FT   VARIANT    1386   1386       S -> F (in HHF1; dbSNP:rs72559718).
FT                                {ECO:0000269|PubMed:24814349}.
FT                                /FTId=VAR_031379.
FT   VARIANT    1387   1387       Missing (in HHF1; severe; high frequency
FT                                in Ashkenazi Jewish patients; defective
FT                                trafficking and lack of surface
FT                                expression).
FT                                {ECO:0000269|PubMed:11226335,
FT                                ECO:0000269|PubMed:15562009,
FT                                ECO:0000269|PubMed:16357843,
FT                                ECO:0000269|PubMed:8923011,
FT                                ECO:0000269|PubMed:9618169,
FT                                ECO:0000269|PubMed:9648840}.
FT                                /FTId=VAR_008538.
FT   VARIANT    1388   1388       S -> Y (in HHF1).
FT                                {ECO:0000269|PubMed:24814349}.
FT                                /FTId=VAR_072947.
FT   VARIANT    1389   1389       L -> P (in HHF1).
FT                                {ECO:0000269|PubMed:24814349}.
FT                                /FTId=VAR_072948.
FT   VARIANT    1393   1393       R -> H (in HHF1; severe; loss of channel
FT                                activity; dbSNP:rs769279368).
FT                                {ECO:0000269|PubMed:9618169,
FT                                ECO:0000269|PubMed:9648840}.
FT                                /FTId=VAR_008655.
FT   VARIANT    1400   1400       G -> R (in HHF1 and PNDM; compound
FT                                heterozygous with L-45 in PNDM;
FT                                dbSNP:rs137852676).
FT                                {ECO:0000269|PubMed:16357843,
FT                                ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_031380.
FT   VARIANT    1418   1418       R -> H (in HHF1; altered intracellular
FT                                trafficking).
FT                                {ECO:0000269|PubMed:15579781,
FT                                ECO:0000269|PubMed:25720052}.
FT                                /FTId=VAR_031381.
FT   VARIANT    1420   1420       R -> C (in HHF1; modest impairment of
FT                                channel function; dbSNP:rs28938469).
FT                                {ECO:0000269|PubMed:10202168,
FT                                ECO:0000269|PubMed:10615958,
FT                                ECO:0000269|PubMed:9769320}.
FT                                /FTId=VAR_008539.
FT   VARIANT    1424   1424       I -> V (in PNDM; overactive channel;
FT                                dbSNP:rs80356653).
FT                                {ECO:0000269|PubMed:16885549}.
FT                                /FTId=VAR_029787.
FT   VARIANT    1436   1436       R -> Q (in HHF1; cannot form a functional
FT                                channel, due to protein instability or
FT                                defective transport to the membrane;
FT                                dbSNP:rs387906407).
FT                                {ECO:0000269|PubMed:10615958}.
FT                                /FTId=VAR_015008.
FT   VARIANT    1450   1450       L -> P (in HHF1).
FT                                {ECO:0000269|PubMed:16429405}.
FT                                /FTId=VAR_031382.
FT   VARIANT    1457   1457       A -> T (in HHF1; dbSNP:rs72559717).
FT                                {ECO:0000269|PubMed:12364426}.
FT                                /FTId=VAR_031383.
FT   VARIANT    1457   1457       A -> V (in HHF1).
FT                                {ECO:0000269|PubMed:24814349}.
FT                                /FTId=VAR_072949.
FT   VARIANT    1471   1471       D -> H (in HHF1).
FT                                {ECO:0000269|PubMed:15562009}.
FT                                /FTId=VAR_031384.
FT   VARIANT    1471   1471       D -> N (in HHF1; dbSNP:rs72559716).
FT                                {ECO:0000269|PubMed:15562009}.
FT                                /FTId=VAR_031385.
FT   VARIANT    1478   1478       G -> R (in HHF1; channels insensitive to
FT                                metabolic inhibition and to activation by
FT                                ADP; dbSNP:rs72559715).
FT                                {ECO:0000269|PubMed:8650576}.
FT                                /FTId=VAR_008656.
FT   VARIANT    1480   1480       N -> I (in HHF1; no effect on cell
FT                                membrane expression; no effect on traffic
FT                                efficiency; dramatically reduced
FT                                potassium channel response to activators
FT                                such as MgADP or to diazoxide).
FT                                {ECO:0000269|PubMed:24814349}.
FT                                /FTId=VAR_072950.
FT   VARIANT    1486   1486       R -> K (in HHF1).
FT                                {ECO:0000269|PubMed:15807877}.
FT                                /FTId=VAR_031386.
FT   VARIANT    1493   1493       R -> Q (in HHF1).
FT                                {ECO:0000269|PubMed:16357843}.
FT                                /FTId=VAR_031387.
FT   VARIANT    1493   1493       R -> W (in HHF1; altered intracellular
FT                                trafficking; dbSNP:rs28936371).
FT                                {ECO:0000269|PubMed:10202168,
FT                                ECO:0000269|PubMed:15579781,
FT                                ECO:0000269|PubMed:9769320}.
FT                                /FTId=VAR_008540.
FT   VARIANT    1505   1505       D -> E (in HHF1; no effect on cell
FT                                membrane expression; no effect on traffic
FT                                efficiency; dramatically reduced
FT                                potassium channel response to activators
FT                                such as MgADP or to diazoxide).
FT                                {ECO:0000269|PubMed:24814349}.
FT                                /FTId=VAR_072951.
FT   VARIANT    1506   1506       E -> K (in HHF1; mild; dominantly
FT                                inherited; channels insensitive to
FT                                metabolic inhibition and to activation by
FT                                ADP; dbSNP:rs137852671).
FT                                {ECO:0000269|PubMed:11018078,
FT                                ECO:0000269|PubMed:12364426}.
FT                                /FTId=VAR_015009.
FT   VARIANT    1507   1507       A -> AAS (in HHF1).
FT                                /FTId=VAR_008657.
FT   VARIANT    1511   1511       I -> S (in HHF1; no effect on cell
FT                                membrane expression; no effect on traffic
FT                                efficiency; dramatically reduced
FT                                potassium channel response to activators
FT                                such as MgADP or to diazoxide).
FT                                {ECO:0000269|PubMed:24814349}.
FT                                /FTId=VAR_072952.
FT   VARIANT    1522   1522       V -> L (in PNDM; highly reduced
FT                                inhibition by ATP when associated whith
FT                                I-229). {ECO:0000269|PubMed:17668386}.
FT                                /FTId=VAR_072953.
FT   VARIANT    1543   1543       L -> P (in HHF1; reduced channels surface
FT                                expression and response to ADP;
FT                                dbSNP:rs72559713).
FT                                {ECO:0000269|PubMed:11867634}.
FT                                /FTId=VAR_015010.
FT   VARIANT    1550   1550       V -> D (in HHF1).
FT                                {ECO:0000269|PubMed:12364426}.
FT                                /FTId=VAR_031388.
FT   VARIANT    1551   1551       L -> V (in HHF1).
FT                                {ECO:0000269|PubMed:12364426}.
FT                                /FTId=VAR_031389.
FT   VARIANT    1572   1572       V -> I (in dbSNP:rs8192690).
FT                                {ECO:0000269|PubMed:10447255,
FT                                ECO:0000269|PubMed:16429405,
FT                                ECO:0000269|PubMed:8923011}.
FT                                /FTId=VAR_008658.
FT   CONFLICT     30     30       A -> V (in Ref. 2; AAB02278/AAB02417/
FT                                AAB02418). {ECO:0000305}.
FT   CONFLICT    157    157       F -> L (in Ref. 3; AAB36699/AAB36700).
FT                                {ECO:0000305}.
FT   CONFLICT    163    163       G -> A (in Ref. 2; AAB02278/AAB02417/
FT                                AAB02418). {ECO:0000305}.
FT   CONFLICT    167    167       L -> V (in Ref. 2; AAB02278/AAB02417/
FT                                AAB02418). {ECO:0000305}.
FT   CONFLICT    256    256       A -> V (in Ref. 3; AAB36699/AAB36700).
FT                                {ECO:0000305}.
FT   CONFLICT    487    487       S -> T (in Ref. 2; AAB02278/AAB02417/
FT                                AAB02418). {ECO:0000305}.
FT   CONFLICT   1069   1070       VL -> AV (in Ref. 2; AAB02278/AAB02417/
FT                                AAB02418). {ECO:0000305}.
FT   CONFLICT   1172   1172       I -> V (in Ref. 3; AAB36699/AAB36700).
FT                                {ECO:0000305}.
FT   CONFLICT   1410   1410       A -> R (in Ref. 3; AAB36699/AAB36700).
FT                                {ECO:0000305}.
FT   CONFLICT   1418   1418       R -> P (in Ref. 3; AAB36699/AAB36700).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1581 AA;  176992 MW;  09CF2EC97899D1CE CRC64;
     MPLAFCGSEN HSAAYRVDQG VLNNGCFVDA LNVVPHVFLL FITFPILFIG WGSQSSKVHI
     HHSTWLHFPG HNLRWILTFM LLFVLVCEIA EGILSDGVTE SHHLHLYMPA GMAFMAAVTS
     VVYYHNIETS NFPKLLIALL VYWTLAFITK TIKFVKFLDH AIGFSQLRFC LTGLLVILYG
     MLLLVEVNVI RVRRYIFFKT PREVKPPEDL QDLGVRFLQP FVNLLSKGTY WWMNAFIKTA
     HKKPIDLRAI GKLPIAMRAL TNYQRLCEAF DAQVRKDIQG TQGARAIWQA LSHAFGRRLV
     LSSTFRILAD LLGFAGPLCI FGIVDHLGKE NDVFQPKTQF LGVYFVSSQE FLANAYVLAV
     LLFLALLLQR TFLQASYYVA IETGINLRGA IQTKIYNKIM HLSTSNLSMG EMTAGQICNL
     VAIDTNQLMW FFFLCPNLWA MPVQIIVGVI LLYYILGVSA LIGAAVIILL APVQYFVATK
     LSQAQRSTLE YSNERLKQTN EMLRGIKLLK LYAWENIFRT RVETTRRKEM TSLRAFAIYT
     SISIFMNTAI PIAAVLITFV GHVSFFKEAD FSPSVAFASL SLFHILVTPL FLLSSVVRST
     VKALVSVQKL SEFLSSAEIR EEQCAPHEPT PQGPASKYQA VPLRVVNRKR PAREDCRGLT
     GPLQSLVPSA DGDADNCCVQ IMGGYFTWTP DGIPTLSNIT IRIPRGQLTM IVGQVGCGKS
     SLLLAALGEM QKVSGAVFWS SLPDSEIGED PSPERETATD LDIRKRGPVA YASQKPWLLN
     ATVEENIIFE SPFNKQRYKM VIEACSLQPD IDILPHGDQT QIGERGINLS GGQRQRISVA
     RALYQHANVV FLDDPFSALD IHLSDHLMQA GILELLRDDK RTVVLVTHKL QYLPHADWII
     AMKDGTIQRE GTLKDFQRSE CQLFEHWKTL MNRQDQELEK ETVTERKATE PPQGLSRAMS
     SRDGLLQDEE EEEEEAAESE EDDNLSSMLH QRAEIPWRAC AKYLSSAGIL LLSLLVFSQL
     LKHMVLVAID YWLAKWTDSA LTLTPAARNC SLSQECTLDQ TVYAMVFTVL CSLGIVLCLV
     TSVTVEWTGL KVAKRLHRSL LNRIILAPMR FFETTPLGSI LNRFSSDCNT IDQHIPSTLE
     CLSRSTLLCV SALAVISYVT PVFLVALLPL AIVCYFIQKY FRVASRDLQQ LDDTTQLPLL
     SHFAETVEGL TTIRAFRYEA RFQQKLLEYT DSNNIASLFL TAANRWLEVR MEYIGACVVL
     IAAVTSISNS LHRELSAGLV GLGLTYALMV SNYLNWMVRN LADMELQLGA VKRIHGLLKT
     EAESYEGLLA PSLIPKNWPD QGKIQIQNLS VRYDSSLKPV LKHVNALIAP GQKIGICGRT
     GSGKSSFSLA FFRMVDTFEG HIIIDGIDIA KLPLHTLRSR LSIILQDPVL FSGTIRFNLD
     PERKCSDSTL WEALEIAQLK LVVKALPGGL DAIITEGGEN FSQGQRQLFC LARAFVRKTS
     IFIMDEATAS IDMATENILQ KVVMTAFADR TVVTIAHRVH TILSADLVIV LKRGAILEFD
     KPEKLLSRKD SVFASFVRAD K
//
